相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases
Gianluigi Savarese et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2020)
Antithrombotic Therapy for Peripheral Revascularisation
Marco De Carlo et al.
CURRENT VASCULAR PHARMACOLOGY (2020)
Pathophysiology of Thrombosis in Peripheral Artery Disease
Aida Habib et al.
CURRENT VASCULAR PHARMACOLOGY (2020)
Antithrombotic Therapy in Lower Extremity Artery Disease
Mislav Vrsalovic et al.
CURRENT VASCULAR PHARMACOLOGY (2020)
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial
J. Wouter Jukema et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)
Victor Aboyans et al.
EUROPEAN HEART JOURNAL (2018)
Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease - A meta-analysis
Eliano P. Navarese et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)
Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial
Frans Moll et al.
JOURNAL OF ENDOVASCULAR THERAPY (2018)
Sustained Effectiveness of Cilostazol After Endovascular Treatment of Femoropopliteal Lesions: Midterm Follow-up From the Sufficient Treatment of Peripheral Intervention by Cilostazol (STOP-IC) Study
Yoshimitsu Soga et al.
JOURNAL OF ENDOVASCULAR THERAPY (2018)
Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease
Sonia S. Anand et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
Sonia S. Anand et al.
LANCET (2018)
Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial
Jeffrey S. Berger et al.
VASCULAR MEDICINE (2018)
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)
Marc P. Bonaca et al.
CIRCULATION (2018)
Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME
Subodh Verma et al.
CIRCULATION (2018)
Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease
W. Schuyler Jones et al.
CIRCULATION (2017)
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Marie D. Gerhard-Herman et al.
CIRCULATION (2017)
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
William R. Hiatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Efficacy of CilostAzol for Below-the-Knee Artery Disease after Balloon AnGioplasty in PatiEnts with Severe Limb Ischemia (CABBAGE Trial)
Yoshimitsu Soga et al.
ANNALS OF VASCULAR SURGERY (2017)
Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50)
Marc P. Bonaca et al.
CIRCULATION (2016)
Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar Insights From the TRA 2°P-TIMI 50 Trial
Marc P. Bonaca et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2016)
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease
Marc P. Bonaca et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease
Ehrin J. Armstrong et al.
JOURNAL OF VASCULAR SURGERY (2015)
Comparative Efficacy and Safety of Different Antiplatelet Agents for Prevention of Major Cardiovascular Events and Leg Amputations in Patients with Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis
Konstantinos Katsanos et al.
PLOS ONE (2015)
Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial
Manesh R. Patel et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2015)
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)
William Schuyler Jones et al.
AMERICAN HEART JOURNAL (2014)
A Prospective Randomized Controlled Clinical Trial on Clopidogrel Combined With Warfarin Versus Clopidogrel Alone in the Prevention of Restenosis After Endovascular Treatment of the Femoropopliteal Artery
Hailei Li et al.
ANNALS OF VASCULAR SURGERY (2013)
Vorapaxar in Patients With Peripheral Artery Disease Results From TRA2°P-TIMI 50
Marc P. Bonaca et al.
CIRCULATION (2013)
Cilostazol Reduces Angiographic Restenosis After Endovascular Therapy for Femoropopliteal Lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol Study
Osamu Iida et al.
CIRCULATION (2013)
Twelve-Month Results of a Randomized Trial Comparing Mono With Dual Antiplatelet Therapy in Endovascularly Treated Patients With Peripheral Artery Disease
Frederik F. Strobl et al.
JOURNAL OF ENDOVASCULAR THERAPY (2013)
Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis
F. Gerald R. Fowkes et al.
LANCET (2013)
Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol
Yoshimitsu Soga et al.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2012)
Management of peripheral arterial interventions with mono or dual antiplatelet therapy-the MIRROR study: a randomised and double-blinded clinical trial
Gunnar Tepe et al.
EUROPEAN RADIOLOGY (2012)
A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication
Eric P. Brass et al.
JOURNAL OF VASCULAR SURGERY (2012)
Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients
Mario Monaco et al.
JOURNAL OF VASCULAR SURGERY (2012)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial
Jill J. F. Belch et al.
JOURNAL OF VASCULAR SURGERY (2010)
Comparison of efficacy of antiplatelet treatments for patients with claudication A meta-analysis
Stefania Basili et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Efficacy of Cilostazol After Endovascular Therapy for Femoropopliteal Artery Disease in Patients With Intermittent Claudication
Yoshimitsu Soga et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: A Study in Long-term Effects)
William R. Hiatt et al.
JOURNAL OF VASCULAR SURGERY (2008)
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
Deepak L. Bhatt et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: A randomized controlled trial
Renate Koppensteiner et al.
JOURNAL OF VASCULAR SURGERY (2006)
Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study
GGN Serneri et al.
EUROPEAN HEART JOURNAL (2004)
Long term prognosis in patients with peripheral arterial disease treated with antiplatelet agents
N Fiotti et al.
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY (2003)
The effect of anticoagulation therapy and graft selection on the ischemic consequences of femoropopliteal bypass graft occlusion: Results from a multicenter randomized clinical trial
MR Jackson et al.
JOURNAL OF VASCULAR SURGERY (2002)
Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: A prospective randomized study
WC Johnson et al.
JOURNAL OF VASCULAR SURGERY (2002)
分享论文
